Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Norgren

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
JAMA Network Open|January 16, 2019
Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID TrialJ Antonio Gutierrez, Hillary Mulder, W Schuyler Jones, et al.
Vascular Medicine (London, England)|July 25, 2019
Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trialCharles W Hopley, Sarah Kavanagh, Manesh R Patel, et al.
Journal of the American Heart Association|May 31, 2021
Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLIDMarc D Samsky, Anne Hellkamp, William R Hiatt, et al.
Vascular Medicine (London, England)|June 4, 2021
Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y<sub>12</sub> inhibitors: Insights from the EUCLID trialJudith Hsia, Sarah T Kavanagh, Charles W Hopley, et al.
Circulation. Cardiovascular Interventions|July 13, 2021
Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID TrialWilliam R Hiatt, Connie N Hess, Marc P Bonaca, et al.
International Angiology : a Journal of the International Union of Angiology|July 9, 2016
Prioritization of treatments for lower extremity peripheral artery disease in low- and middle-income countriesF Gerald Fowkes, Rachel B Forster, Carol E Levin, et al.
Circulation. Cardiovascular Quality and Outcomes|July 4, 2020
Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID TrialChandler A Long, Hillary Mulder, F Gerry R Fowkes, et al.
American Heart Journal|September 20, 2020
CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID TrialJ Antonio Gutierrez, Gretchen M Heizer, W Schuyler Jones, et al.
Circulation. Cardiovascular Quality and Outcomes|September 1, 2020
Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID TrialMarat Fudim, Charles W Hopley, Zhen Huang, et al.
American Heart Journal|November 30, 2019
Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trialRachael Ward, Zhen Huang, Frank W Rockhold, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
JAMA Network Open|January 16, 2019
Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID TrialJ Antonio Gutierrez, Hillary Mulder, W Schuyler Jones, et al.
Vascular Medicine (London, England)|July 25, 2019
Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trialCharles W Hopley, Sarah Kavanagh, Manesh R Patel, et al.
Journal of the American Heart Association|May 31, 2021
Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLIDMarc D Samsky, Anne Hellkamp, William R Hiatt, et al.
Vascular Medicine (London, England)|June 4, 2021
Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y<sub>12</sub> inhibitors: Insights from the EUCLID trialJudith Hsia, Sarah T Kavanagh, Charles W Hopley, et al.
Circulation. Cardiovascular Interventions|July 13, 2021
Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID TrialWilliam R Hiatt, Connie N Hess, Marc P Bonaca, et al.
International Angiology : a Journal of the International Union of Angiology|July 9, 2016
Prioritization of treatments for lower extremity peripheral artery disease in low- and middle-income countriesF Gerald Fowkes, Rachel B Forster, Carol E Levin, et al.
Circulation. Cardiovascular Quality and Outcomes|July 4, 2020
Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID TrialChandler A Long, Hillary Mulder, F Gerry R Fowkes, et al.
American Heart Journal|September 20, 2020
CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID TrialJ Antonio Gutierrez, Gretchen M Heizer, W Schuyler Jones, et al.
Circulation. Cardiovascular Quality and Outcomes|September 1, 2020
Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID TrialMarat Fudim, Charles W Hopley, Zhen Huang, et al.
American Heart Journal|November 30, 2019
Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trialRachael Ward, Zhen Huang, Frank W Rockhold, et al.
Pageof 8